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Purpose of the study
Co-infection with HBV and HIV-1 is particularly common
among patients from sub-Saharan origin, because of the
high prevalence of HBV and HIV-1 infection. Differences
in HBV subtypes, hepatitis B early antigenemia (HBeAg),
and drug resistance mutations can influence the outcome
in patients with chronic HBV. The aim of this study was to
examine the HBV marker characteristics in HIV/HBV co-
infected patients originating from Europe and sub-Saha-
ran Africa attending a Parisian hospital, and to determine
risk factors for liver-related morbidity.
Methods
A total of 100 consecutive HIV-1 infected patients with
chronic HBV infection, followed up for at least 2 years,
were included in the study. Patients were classified into
two groups according to their geographical origin: Group
1 (n = 35 from Europe); Group 2 (n = 65 from sub-Saha-
ran Africa).
Summary of results
The studied population included 39 females (14.3% of
Group 1 and 52.3% of Group 2, p < 0.001). The predom-
inant route of HBV and HIV transmission was homosex-
ual in Group 1, while in Group 2, perinatal and
horizontal infection early in childhood where thought to
be the main routes of HBV transmission, along with het-
erosexual transmission of HIV-1. HBV genotypes could be
determined in 63 patients (30/35 from Group 1, 33/65
from Group 2). Patients in Group 1 were infected with
genotype A (21), genotype G (two), genotype D (two),
genotype B (one) genotype C (one), and genotype E
(three), whereas patients in Group 2 were infected with
genotype E (24) and genotype A (nine). At baseline, the
number of HBeAg-positive patients was significantly
higher in Group 1 (60.4%) than in Group 2 (24.6%) (p =
0.001). Thirteen patients in Group 2 were co-infected with
HDV. Lamivudine was administered to 83 patients. Of the
38 patients with available viral genotype data, 19 (14 in
Group 1 and five in Group 2) were identified as harbour-
ing mutations associated with lamivudine resistance. The
predominant mutations were L180M+M204V (nine
patients), V173L+L180M+M204V (eight patients), and
L180M+M204I (two patients). Advanced liver disease was
diagnosed in 19 patients during the follow-up.
Conclusion
The two groups of co-infected patients differed in the ratio
of males to females, the route of transmission and the pre-
dominant HBV genotype. Patients in Group 2 had lower
HBV viral load and were more often HBeAg-negative. Nei-
ther HBV genotype nor geographical origin were statisti-
cally associated with advanced liver disease.
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